Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 26Small Cell Lung Carcinoma 10Sarcoma 8Breast Neoplasms 8Carcinoma, Hepatocellular 7Lung Neoplasms 6Stomach Neoplasms 5Triple Negative Breast Neoplasms 4Ovarian Neoplasms 4Esophageal Squamous Cell Carcinoma 4Carcinoma 4Non-squamous Non-small Cell Lung Cancer 3NSCLC 3Glioma 3Uterine Cervical Neoplasms 2Urogenital Neoplasms 2Thyroid Neoplasms 2Pheochromocytoma 2Paraganglioma 2Neoplasms 2Liver Neoplasms 2Gynecological Cancer 2Extensive Stage Small Cell Lung Cancer 2Esophageal Neoplasms 2Endometrial Neoplasms 2Digestive System Neoplasms 2Carcinoma, Ovarian Epithelial 2Advanced Solid Tumor 2Squamous Non-small Cell Lung Cancer 1Squamous Cell Carcinoma of Head and Neck 1

Interventions

Thyrotropin Alfa 2apatinib 1anlotinib 1Sorafenib 1Iodine-131 1Injections 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Differentiated Thyroid Cancer × anlotinib × Clear all
NCT02586337 2019-05-21

Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2/3 Unknown
113 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡